- Merck KGaA (MKGAF) inks a second collaboration deal with Beijing-based BeiGene.
- The new deal is a licensing, development, and commercialization agreement for BeiGene-290, a preclinical PARP inhibitor.
- The terms of the agreement call for German Merck to take on the development and commercialization responsibilities for '290 outside of China.
- Milestone payments to BeiGene could reach $232M.
- BeiGene also received an undisclosed upfront payment. (PR)